VIDEO: Ocuphire shares latest in oral tablet for treatment of retinal disease

Issue: June 25, 2022

ByMina Sooch

ByDavid W. Mullin

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Mina Sooch, founder and CEO of Ocuphire Pharma, updates the latest research in the development of APX3330 oral tablet to treat retinal disease.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interviews

Disclosures: Sooch reports being founder and CEO of Ocuphire Pharma.

Read more about

diabetic retinopathy

anti-vegf

retinal disease

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

• Facebook
• Twitter
• LinkedIn
• Email
• Print
• Comment